Drugs / AZD9574
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07590934 | Jun 2026 → Sep 2029 expected | metastatic prostate carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07181161 | Oct 2025 → Jan 2029 expected | metastatic prostate carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05797168 | Jun 2023 → Aug 2028 expected | endometrial cancer, lung adenocarcinoma, ovarian cancer, squamous cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05417594 | Jun 2022 → Feb 2028 expected | high grade malignant neoplasm | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05123482 | Oct 2021 → Sep 2027 expected | biliary tract cancer, breast carcinoma, endometrial cancer, non-small cell squamous lung carcinoma +1 | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD9574 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05123482 ↗ |
| Known as | Palacaparib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05797168 ↗ |
| Action | Inhibit | “AZD9574 is a PARP inhibitor that stops the PARP protein from doing its repair work in damaged cancer cells” NCT05123482 ↗ |
| Modality | Small molecule | “Oral PARP inhibitor” NCT05797168 ↗ |
| Route | Oral | “Participants will receive AZD9574 orally.” NCT05417594 ↗ |
| Target | PARP1 | “a blood-brain barrier (BBB) penetrant selective inhibitor of PARP1” PMID 37967136 ↗ Apr 2024 |